Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.

Abstract

This study aimed to compare the efficacy of neoadjuvant systemic therapy (NST) with solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel in human epidermal growth factor receptor 2 (HER2)-low-positive and HER2-zero breast cancers. A total of 430 patients receiving 2-weekly dose-dense epirubicin and cyclophosphamide (EC) followed by 2-weekly paclitaxel (Sb-P, Lps-P, or Nab-P), or 3-weekly EC followed by 3-weekly docetaxel for NST were enrolled in the study. In HER2-low-positive patients, the pathological complete response (pCR) rate in Nab-P group was significantly higher than that in the other three paclitaxel groups (2.8 % in Sb-P group, 4.7 % in Lps-P group, 23.2 % in Nab-P group and 3.2 % in docetaxel group, p < 0.001). In HER2-zero patients, the pCR rate did not differ significantly among the four paclitaxel groups (p = 0.278). The NST regimen containing Nab-P could be considered a promising treatment option in HER2-low-positive breast cancer.

• Authors: Wenjie Shi, Xinyu Wan, Ye Wang, Jinzhi He, Xiaofeng Huang, Yinggang Xu, Weiwei Zhang, Rui Chen, Lexin Wang, Ran Zheng, Lingjun Ma, Xuan Li, Lu Xu, Xiaoming Zha, Jue Wang
• Journal: Nanomedicine : nanotechnology, biology, and medicine (Nanomedicine) Vol. 49 Pg. 102666 (04 2023) ISSN: 1549-9642 [Electronic] United States
• PMID: 36889422 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023. Published by Elsevier Inc.

Chemical References

• Albumin-Bound Paclitaxel
• Docetaxel
• Lipopolysaccharides
• Cyclophosphamide
• Epirubicin
• Paclitaxel
• Albumins
• Receptor, ErbB-2

Topics

• Humans
• Female
• Breast Neoplasms (pathology)
• Albumin-Bound Paclitaxel (therapeutic use)
• Neoadjuvant Therapy
• Docetaxel (therapeutic use)
• Lipopolysaccharides
• Cyclophosphamide (therapeutic use)
• Epirubicin (therapeutic use)
• Paclitaxel (therapeutic use)
• Albumins
• Receptor, ErbB-2 (metabolism)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Nanoparticles
• Treatment Outcome